MX2014009015A - Stable amorphous raltegravir potassium premix and process for the preparation thereof. - Google Patents

Stable amorphous raltegravir potassium premix and process for the preparation thereof.

Info

Publication number
MX2014009015A
MX2014009015A MX2014009015A MX2014009015A MX2014009015A MX 2014009015 A MX2014009015 A MX 2014009015A MX 2014009015 A MX2014009015 A MX 2014009015A MX 2014009015 A MX2014009015 A MX 2014009015A MX 2014009015 A MX2014009015 A MX 2014009015A
Authority
MX
Mexico
Prior art keywords
preparation
stable amorphous
raltegravir potassium
amorphous raltegravir
potassium premix
Prior art date
Application number
MX2014009015A
Other languages
Spanish (es)
Inventor
Makrand Avachat
Surinder Kumar Arora
Dnyaneshwar Tukaram Singare
Amol Dattatreya Galande
Purna Chandra Ray
Dilip Gopalkrishna Saoji
Girij Pal Singh
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2014009015A publication Critical patent/MX2014009015A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a stable amorphous Raltegravir potassium premix, method of making and pharmaceutical composition thereof.
MX2014009015A 2012-01-25 2013-01-25 Stable amorphous raltegravir potassium premix and process for the preparation thereof. MX2014009015A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN72KO2012 2012-01-25
PCT/IB2013/050643 WO2013111100A1 (en) 2012-01-25 2013-01-25 Stable amorphous raltegravir potassium premix and process for the preparation thereof

Publications (1)

Publication Number Publication Date
MX2014009015A true MX2014009015A (en) 2014-12-08

Family

ID=47754907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009015A MX2014009015A (en) 2012-01-25 2013-01-25 Stable amorphous raltegravir potassium premix and process for the preparation thereof.

Country Status (12)

Country Link
US (1) US20150328215A1 (en)
EP (1) EP2806857A1 (en)
JP (1) JP2015504913A (en)
KR (1) KR20140114406A (en)
CN (1) CN104093400A (en)
AU (1) AU2013213255A1 (en)
BR (1) BR112014018247A8 (en)
CA (1) CA2863575A1 (en)
MX (1) MX2014009015A (en)
RU (1) RU2014134257A (en)
WO (1) WO2013111100A1 (en)
ZA (1) ZA201405247B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015140765A1 (en) * 2014-03-21 2015-09-24 Mylan Laboratories Ltd. A premix of crystalline raltegravir potassium salt and a process for the preparation thereof
CN104146949A (en) * 2014-08-29 2014-11-19 宁夏泰瑞制药股份有限公司 Premixing agent for tiamulin fumarate, and preparation method thereof
TWI790189B (en) 2015-01-02 2023-01-21 美商梅拉洛伊卡公司 Bacterial compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL161337A0 (en) 2001-10-26 2004-09-27 Angeletti P Ist Richerche Bio N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
UA87884C2 (en) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Potassium salt of an hiv integrase inhibitor
CN101161244A (en) * 2006-10-13 2008-04-16 上海世康特制药有限公司 Nimodipine tablet and its preparing method
WO2010140156A2 (en) 2009-06-02 2010-12-09 Hetero Research Foundation Novel polymorphs of raltegravir potassium
WO2010143207A1 (en) * 2009-06-11 2010-12-16 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
WO2011024192A2 (en) * 2009-07-27 2011-03-03 Matrix Laboratories Ltd Novel polymorphs of raltegravir
SI2796458T1 (en) * 2010-04-01 2018-04-30 Teva Pharmaceutical Industries Ltd. Crystalline raltegravir sodium salts
US8962833B2 (en) * 2010-05-25 2015-02-24 Hetero Research Foundation Salts of raltegravir

Also Published As

Publication number Publication date
US20150328215A1 (en) 2015-11-19
RU2014134257A (en) 2016-03-20
BR112014018247A2 (en) 2017-06-20
ZA201405247B (en) 2015-12-23
KR20140114406A (en) 2014-09-26
EP2806857A1 (en) 2014-12-03
BR112014018247A8 (en) 2017-07-11
JP2015504913A (en) 2015-02-16
CA2863575A1 (en) 2013-08-01
WO2013111100A1 (en) 2013-08-01
AU2013213255A9 (en) 2016-06-16
AU2013213255A1 (en) 2014-08-07
WO2013111100A9 (en) 2014-08-14
CN104093400A (en) 2014-10-08

Similar Documents

Publication Publication Date Title
WO2012156998A3 (en) Amorphous mirabegron and processes for crystal forms of mirabegron
MD20150091A2 (en) Anti-viral compounds
IN2015KN00262A (en)
MX2011008262A (en) Substituted spiro-amides as b1r modulators.
EA033455B1 (en) Crystalline forms of substituted 5-fluoro-1h-pyrazolopyridines, processes for preparing same, use thereof for producing a medicament, medicament and method of treatment based thereof
IN2015KN00323A (en)
MX370649B (en) Process for the preparation of teneligliptin.
MX2015005891A (en) Polymorphic forms of suvoroxant.
MY195343A (en) A Novel Phtalazinone Derivatives and Manufacturing Process Thereof
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
UA116889C2 (en) COMPOSITION COMPRISING A MIXTURE OF CD95-Fc ISOFORMS
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
MX2016008369A (en) Pharmaceutical composition containing palonosetron.
WO2013164839A3 (en) Amorphous form of apixaban, process of preparation and compositions thereof
MX2017001487A (en) Sofosbuvir in crystalline form and process for its preparation.
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
WO2014068586A3 (en) Solid oral compositions of tolvaptan
EP2700322A4 (en) Composition containing scirpusin b, and process for producing composition containing scirpusin b
MX2015003034A (en) Syringe containing a composition, especially a pharmaceutical composition, comprising immunoglobins, method for the production thereof and use of same.
EP2742946A4 (en) Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof
MX2014009015A (en) Stable amorphous raltegravir potassium premix and process for the preparation thereof.
MX2012010443A (en) Process for the preparation of 5-substituted 1-alkyltetrazoles.
MX2012010317A (en) β-hydroxyalkylamides, method for their production and use thereof.
IN2014DN09451A (en)
EP2575465A4 (en) Salts of raltegravir